PA-PHLEXGLOBAL
6.4.2016 09:01:31 CEST | Business Wire | Press release
Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry today announces the newest and most feature rich release of PhlexEview, its market leading eTMF solution.
Now with more capabilities than ever to optimize TMF management, PhlexEview 4 adds intelligent new ways of working designed specifically to enhance the user experience, maximize efficiency, facilitate compliance and improve oversight.
PhlexEview 4 will enable users to get more out of an eTMF system than ever before. The innovative solutions and features span core functionality from study setup, quick and easy document submission & authoring capabilities through to real-time onscreen TMF completeness reporting, ensuring overall TMF quality and inspection readiness.
Dynamic, intelligent placeholder technology will define where documents in the eTMF are expected, automatically matching documents created or dragged and dropped to the correct placeholder. Users can pro-actively manage on-going trial events and create placeholders in the appropriate sections for event driven document management.
Wizard driven eTMF completeness provides pro-active study management through real-time oversight. Configurable role specific landing page dashboards provide overall completeness, quality and timeliness statuses for trial, country and site TMFs.
PhlexEview 4 also enhances Phlexglobal’s unique flexible services model that allows clients to take on or delegate TMF business processing to Phlexglobal through new processing work allocation features on a study by study basis. Phlexglobal can provide expert resources to complete processing at a moment’s notice.
“PhlexEview 4 really is next generation eTMF technology. We believe its features offer the smartest solution around and its release places Phlexglobal firmly at the forefront of the eTMF market” stated Rick Riegel, CEO of Phlexglobal.
For further information on or a demonstration of PhlexEview 4, please contact: info@phlexglobal.com
About Phlexglobal
Phlexglobal is a specialist provider of both industry leading eTMF technology solutions and expert TMF & eTMF technology-enabled services. Offering a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise, we deliver a range of flexible, targeted solutions to meet business needs.
More information can be found at http://www.phlexglobal.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005092/en/
Contact:
Phlexglobal Ltd
Gillian Gittens, head of marketing
Tel:
+44(0)1494 720420
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aresbank Strengthens Trade Finance and Correspondent Banking Compliance with SymphonyAI8.10.2026 09:55:00 CEST | Press release
Specialist corporate bank connecting Europe, Middle East and North Africa, adopts a platform built to scale as regulations and trade volumes evolve As a specialized corporate and trade finance bank in the MENA region, Aresbank manages risk and moves money across some of the most sensitive trade corridors between Europe, the Middle East and North Africa. Operating in a highly regulated environment, Aresbank turned to SymphonyAI, a global leader in Vertical AI whose financial crime compliance platform already spans retail, commercial and correspondent banking, to strengthen its transaction monitoring framework across trade finance and correspondent banking. Headquartered in Madrid, the bank's business centers on trade instruments, including correspondent banking, documentary credits, international guarantees and multi-currency credit lines that connect European and MENA markets. Correspondent banking carries a distinct risk profile, and trade finance flows in the region remain a focus fo
Fortune Media and Great Place To Work Name Experian As One Of The ‘100 Best Companies to Work For Europe’ in 2026 for Second Year8.10.2026 09:00:00 CEST | Press release
Great Place To Work® and Fortune Europe have recognised Experian as one of the Fortune 100 Best Companies to Work For™ Europe for the second-year running. The 100 Best Companies to Work For Europe list is a comprehensive recognition for business excellence and employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Great Place To Work evaluates confidential feedback from employees, validating against HR data from participating companies. Only companies with consistently high survey responses from employees — regardless of their role, department, or status in the company — are honored with placement on the list. Eligible companies have 500 or more employees and were represented on at least one national Best Workplaces™ List in Europe. Jacky Simmonds, Chief People Officer, Experian, said: “We are thrilled to being named one of the Fortune 100 Best Companies to Work For™ in Europe for the second year in a row. It’s an incredibly proud moment for us at Experian
Value Group Brings Its Integrated Global IROPS Management Model to the World Aviation Festival8.10.2026 08:32:00 CEST | Press release
Value Group, a leading provider of integrated aviation disruption management solutions, returns to the World Aviation Festival as a Gold Sponsor, reinforcing its role in the evolution of airline disruption management. From 13 to 15 October at FIL in Lisbon, the event is one of the aviation industry’s leading international technology conferences and exhibitions, bringing together airlines, airports and travel technology companies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007885823/en/ Thomas Sergnese, Co-CEO & Chief Commercial Officer and Daniele Bocchieri, Co-CEO & Chief Operating Officer At stand 1-180, Value Group will showcase the evolution of its integrated disruption management model and the RUBIK digital ecosystem, demonstrating how technology, operations and governance can work together as one connected system to manage irregular operations more effectively at both global and local level. Over the p
Colruyt Group Crosses the 150 Store Milestone With Rollout of Toshiba ELERA® Self Service Store Deployments8.10.2026 07:30:00 CEST | Press release
Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium Toshiba Global Commerce Solutions today announced the successful deployment of its ELERA® Self Service solution across 144 Colruyt Group stores: Okay, Okay City, Spar Colruyt Group and Bio-Planet. Today, 454 self-checkout systems have already been installed year-to-date across 150 stores. The project continues to expand, with an additional 51 stores planned in 2026 and further rollout in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007465701/en/ Toshiba’s ELERA® Self Service successfully deployed across Okay, Okay City, Spar Colruyt Group and Bio-Planet stores in Belgium. The deployment was designed to support a fast, intuitive, and customer-friendly checkout experience, while maintaining the personal interaction that remains important within the convenience retail environment. Across the
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older8.10.2026 07:00:00 CEST | Press release
New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of life in adults with prurigo nodularis up to 148 weeks, and people with atopic dermatitis aged 12 and older up to 152 weeks2,3 Phase II pediatric data will also be presented, with nemolizumab driving meaningful and sustained improvements in children aged 2-11 years with moderate-to-severe atopic dermatitis4 Alongside a product theatre exploring how targeted IL-31 treatment may impact patient outcomes, these findings reinforce Galderma's leadership in advancing treatment goals in atopic dermatitis and prurigo nodularis Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new da
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom